The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care

Adoptive immunotherapy—in particular, T-cell therapy—has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Saglio, Francesco, Hanley, Patrick J., Bollard, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society for Cellular Therapy. Published by Elsevier Inc. 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928596/
https://www.ncbi.nlm.nih.gov/pubmed/24438896
http://dx.doi.org/10.1016/j.jcyt.2013.11.010
_version_ 1782304290563424256
author Saglio, Francesco
Hanley, Patrick J.
Bollard, Catherine M.
author_facet Saglio, Francesco
Hanley, Patrick J.
Bollard, Catherine M.
author_sort Saglio, Francesco
collection PubMed
description Adoptive immunotherapy—in particular, T-cell therapy—has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.
format Online
Article
Text
id pubmed-3928596
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International Society for Cellular Therapy. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-39285962015-02-01 The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care Saglio, Francesco Hanley, Patrick J. Bollard, Catherine M. Cytotherapy Article Adoptive immunotherapy—in particular, T-cell therapy—has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology. International Society for Cellular Therapy. Published by Elsevier Inc. 2014-02 2014-01-15 /pmc/articles/PMC3928596/ /pubmed/24438896 http://dx.doi.org/10.1016/j.jcyt.2013.11.010 Text en Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Saglio, Francesco
Hanley, Patrick J.
Bollard, Catherine M.
The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title_full The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title_fullStr The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title_full_unstemmed The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title_short The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
title_sort time is now: moving toward virus-specific t cells after allogeneic hematopoietic stem cell transplantation as the standard of care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928596/
https://www.ncbi.nlm.nih.gov/pubmed/24438896
http://dx.doi.org/10.1016/j.jcyt.2013.11.010
work_keys_str_mv AT sagliofrancesco thetimeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare
AT hanleypatrickj thetimeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare
AT bollardcatherinem thetimeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare
AT sagliofrancesco timeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare
AT hanleypatrickj timeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare
AT bollardcatherinem timeisnowmovingtowardvirusspecifictcellsafterallogeneichematopoieticstemcelltransplantationasthestandardofcare

Ejemplares similares